Elevated Angiotensin 1–7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients with Heart Failure with Potential Link to COVID-19 Patients
By LabMedica International staff writers Posted on 04 Aug 2020 |
![Image: Structure of the ACE2 (angiotensin-converting enzyme 2) protein (Photo courtesy of Wikimedia Commons) Image: Structure of the ACE2 (angiotensin-converting enzyme 2) protein (Photo courtesy of Wikimedia Commons)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2020-08-04/GMS-090B.jpg)
Image: Structure of the ACE2 (angiotensin-converting enzyme 2) protein (Photo courtesy of Wikimedia Commons)
A high ratio of angiotensin 1-7 to angiotensin II (Ang 1–7/Ang II ratio), was found to be an independent and incremental predictor of beneficial outcomes, higher survival rate, and decreased hospitalization duration for patients with heart failure and possibly in patients with cardiovascular complications due to COVID-19.
The enzyme ACE2 (angiotensin-converting enzyme 2) and the peptide Ang 1–7 are endogenous negative regulators of the renin-angiotensin system exerting cardioprotective effects in models of heart failure. ACE2 lowers blood pressure by catalyzing the hydrolysis of angiotensin II (a vasoconstrictor peptide) into angiotensin (a vasodilator). It counters the activity of the related angiotensin-converting enzyme (ACE) by reducing the amount of angiotensin II. ACE2 is not only an enzyme but also a functional receptor on cell surfaces for both SARS-CoV (SARS coronavirus) and SARS-CoV-2 (COVID-19), and is highly expressed in the heart, testis, kidneys, and lungs, and shed into the plasma.
Since clinical trials have shown that recombinant human ACE2 markedly increased plasma Ang 1–7 and lowered Ang II levels, investigators at the University of Alberta (Edmonton, Canada) hypothesized that the dynamic state of this renin-angiotensin system protective arm could influence long-term outcomes in patients with heart failure.
To test this theory, the investigators examined circulating angiotensin peptide levels in the blood of 110 individuals who were experiencing heart failure due to a heart attack or stroke. Comprehensive circulating and equilibrium levels of plasma angiotensin peptide profiles were assessed using novel liquid chromatography-mass spectrometry/mass spectroscopy techniques.
Results revealed that circulating and equilibrium angiotensin peptide levels strongly correlated in the patient group. Elevated Ang 1–7/Ang II ratios were associated with improved survival and lower hospitalization duration. In contrast, individual Ang 1–7 and Ang II peptide levels failed to predict all-cause mortality or hospitalization duration in the patient group.
Senior author Dr. Gavin Oudit, professor of cardiology at the University of Alberta, said, "The discovery of the ratio test highlights the bridge between cardiovascular disease and COVID-19 and the pivotal role ACE2 plays in both diseases. In heart failure patients, when your ACE2 is working well, your mortality is much lower, hospitalization is reduced. Now we need to see the parallels in patients with COVID-19. We are fortunate that we have the understanding of ACE2, and we have both the research and therapeutic tools to target this pathway for patients with heart failure, and also now patients with COVID-19. The crisis is an opportunity to better help all of our patients."
The study was published in the June 25, 2020, online edition of the journal Circulation: Heart Failure.
Related Links:
University of Alberta
The enzyme ACE2 (angiotensin-converting enzyme 2) and the peptide Ang 1–7 are endogenous negative regulators of the renin-angiotensin system exerting cardioprotective effects in models of heart failure. ACE2 lowers blood pressure by catalyzing the hydrolysis of angiotensin II (a vasoconstrictor peptide) into angiotensin (a vasodilator). It counters the activity of the related angiotensin-converting enzyme (ACE) by reducing the amount of angiotensin II. ACE2 is not only an enzyme but also a functional receptor on cell surfaces for both SARS-CoV (SARS coronavirus) and SARS-CoV-2 (COVID-19), and is highly expressed in the heart, testis, kidneys, and lungs, and shed into the plasma.
Since clinical trials have shown that recombinant human ACE2 markedly increased plasma Ang 1–7 and lowered Ang II levels, investigators at the University of Alberta (Edmonton, Canada) hypothesized that the dynamic state of this renin-angiotensin system protective arm could influence long-term outcomes in patients with heart failure.
To test this theory, the investigators examined circulating angiotensin peptide levels in the blood of 110 individuals who were experiencing heart failure due to a heart attack or stroke. Comprehensive circulating and equilibrium levels of plasma angiotensin peptide profiles were assessed using novel liquid chromatography-mass spectrometry/mass spectroscopy techniques.
Results revealed that circulating and equilibrium angiotensin peptide levels strongly correlated in the patient group. Elevated Ang 1–7/Ang II ratios were associated with improved survival and lower hospitalization duration. In contrast, individual Ang 1–7 and Ang II peptide levels failed to predict all-cause mortality or hospitalization duration in the patient group.
Senior author Dr. Gavin Oudit, professor of cardiology at the University of Alberta, said, "The discovery of the ratio test highlights the bridge between cardiovascular disease and COVID-19 and the pivotal role ACE2 plays in both diseases. In heart failure patients, when your ACE2 is working well, your mortality is much lower, hospitalization is reduced. Now we need to see the parallels in patients with COVID-19. We are fortunate that we have the understanding of ACE2, and we have both the research and therapeutic tools to target this pathway for patients with heart failure, and also now patients with COVID-19. The crisis is an opportunity to better help all of our patients."
The study was published in the June 25, 2020, online edition of the journal Circulation: Heart Failure.
Related Links:
University of Alberta
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear
Channels
Clinical Chemistry
view channel![Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT) Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-10/MIT-Printed-Ion-01-press_0.jpg)
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more![Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University) Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-14/Spinning-Glowing (1).jpg)
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more![Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University) Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-04/ac3c04435_0004.jpg)
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreHematology
view channel![Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia) Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/C3_DBS_Website.2.jpg)
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more![Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols) Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-08/donor-testing-1.jpg)
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more![Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health) Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-20/news-7.jpg)
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more![Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health) Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-02-08/inserting-hb-variant-cartridge.jpg)
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel![Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock) Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-22/shutterstock_1604213059_1.jpg)
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more![Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston) Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-19/false-color-scanning-election-micrograph-lung-cancer-cells-sinha-image-1_n.jpg)
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more![Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF) Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-12/59385226_m_normal_none.jpg)
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read moreMicrobiology
view channel![Image: The DxI 9000 Analyzer innovations address today’s speed, reliability, reproducibility, quality, and menu expansion demands (Photo courtesy of Beckman Coulter) Image: The DxI 9000 Analyzer innovations address today’s speed, reliability, reproducibility, quality, and menu expansion demands (Photo courtesy of Beckman Coulter)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-26/DxI_9000_System__angle.jpg)
New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
According to the World Health Organization (WHO), an estimated 354 million individuals globally are afflicted with chronic hepatitis B or C. These viruses are the leading causes of liver cirrhosis, liver... Read more![Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock) Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-25/shutterstock_2132233813.jpg)
1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read morePathology
view channel![Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo) Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-26/pars_imaging_slides.jpg)
AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more![Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF) Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-25/25128898_m_normal_none.jpg)
New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read moreTechnology
view channel![Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz) Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/new-diagnostic-tool-ac.jpg)
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more![Image: The electrochemical sensor detects HPV-16 and HPV-18 with high specificity (Photo courtesy of 123RF) Image: The electrochemical sensor detects HPV-16 and HPV-18 with high specificity (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2023-12-21/SDD-294799669.jpg)
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more![Image: The self-heating microfluidic devices can help detect diseases without expensive lab equipment (Photo courtesy of MIT) Image: The self-heating microfluidic devices can help detect diseases without expensive lab equipment (Photo courtesy of MIT)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2023-12-15/SDD-294799594.jpg)
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more![Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University) Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2023-12-01/SDD-294799462.jpg)
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel![Image: ESCMID has modernized its branding and communications (Photo courtesy of ESCMID) Image: ESCMID has modernized its branding and communications (Photo courtesy of ESCMID)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-11/ESCMID-branding-relaunch.jpg)
ECCMID Congress Name Changes to ESCMID Global
Over the last few years, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) has evolved remarkably. The society is now stronger and broader than ever before... Read more![Image: Both companies will invest EURO 150 million in research, development, and distribution of the Vivalytic analysis platform (Photo courtesy of Bosch) Image: Both companies will invest EURO 150 million in research, development, and distribution of the Vivalytic analysis platform (Photo courtesy of Bosch)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-10/einfuehrung_kartusche_vivalytic_4104_img_w760.jpg)
Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
Given the presence of so many diseases, determining whether a patient is presenting the symptoms of a simple cold, the flu, or something as severe as life-threatening meningitis is usually only possible... Read more![Image: The Fast Track Diagnostics unit, a small collection of PCR testing products, is part of Siemens’ Diagnostics business (Photo courtesy of Siemens) Image: The Fast Track Diagnostics unit, a small collection of PCR testing products, is part of Siemens’ Diagnostics business (Photo courtesy of Siemens)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-19/mdx_dna_helix.jpg)